to shorten the duration, reduce the number and decrease the sevity of common cold symptoms in otherwise healthy human adult volunteers
Conditions
Interventions
Product Name: Zicam RapidMelts
Product Code: n/a
Pharmaceutical Form: Tablet
INN or Proposed INN: Zinc acetate USP
CAS Number: 5970-45-6
Current Sponsor code: -
Other descriptive name: -
Concentration
Sponsors
Matrixx Initiatives Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Onset of common cold symptoms within 24 hours preceding pre-enrolment screening.Male and female volunteers 18 years of age and above.In good general health other than the common cold. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Cold symptoms for more than 24 hours at time of enrolment.History of perennial allergic rhinitis, asthma or any other chronic respiratory disease.Prior history of adverse reaction to zinc, calcium or any of the inactive ingredients of Zicam RapidMelts tablets.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Shorten the duration of common cold symptoms;Secondary Objective: Reduce the number of common cold symptoms2. Decrease the severity of common cold symptoms Decrease the severity of common cold symptoms;Primary end point(s): End of common cold symptoms | — |
Countries
United Kingdom
Outcome results
None listed